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Asia accounts for about 60% of the world’s population and
half the global burden of cancer [1]. Due to the diverse
economic development across the Asian continent,
countries have highly variable health services development
and healthcare infrastructure. Thus, there is disparity in
access to services, especially resource intensive cancer
management. All countries in Asia, except Japan are
defined by the UN as ‘less developed regions’ and this
reflects the limited resources in general. This presentation
aims to describe the demographic characteristics of cancer
in Asia, and highlight the challenges and main advance-
ments of cancer imaging across this region.
Lung cancer is the most common cancer in men
(35.2/100,000 persons) and breast cancer the most com-
mon cancer in women (29.1/100,000 women) in Asia.
The incidence rate of breast cancer in Asia is about 1/3
compared to North America (NA) and Western Europe
(WE), although it is on a steady rise. However, the five
year prevalence rate is manifold lower indicating that in
proportion, there are fewer cancer survivors in Asia. With
the exceptions of Japan, South Korea and Taiwan,
resources in most countries are inadequate for popula-
tion-based organised screening mammography pro-
grammes. However, it is less clear if organised screening
would be a cost-effective programme in Asia, due to the
lower incidence rate as well as reduced sensitivity of
mammography in Asian women with higher density breast
tissue [2], and there is evidence that supplemental
ultrasound screening increases the sensitivity for cancer
detection in women with dense breasts [3].
Notably, in South East Asia (SEA) and East Asia (EA)
compared to the rest of the world, the incidences of
liver cancer, oesophageal cancer, stomach cancer and
nasopharyngeal cancer are relatively high, although on
the decline. Liver cancer is the second and third most
common cancer in men in SEA and EA respectively,
and fifth most common cancer in women. More than
70% of the new cases of liver cancer are from Asia, of
which 50% are from China. Recent studies have
advanced the use of gadolinium ethoxybenzyl dimeglu-
mine (Gd-EOB-DTPA) enhanced MRI for its superior
sensitivity for the detection of hepatocellular carcinoma,
especially small tumors [4], and 11C-acetate PET ima-
ging for detection of well-differentiated tumors [5].
Oesophageal cancer is the fifth most common cancer in
EA men. Asia accounts to about 75% of new cases, spe-
cifically the ‘asian oesophageal cancer belt’ that extends
from Turkey to Mongolia and Western/Northern China.
The majority of these are squamous cell carcinoma in
histology. Studies have found 18F-Fluorodeoxyglucose
(FDG) PET to be useful in disease staging (particularly
upstaging), and predictive of outcome of neo-adjuvant
chemotherapy and disease survival [6]. Nasopharyngeal
carcinoma is the sixth and fourteenth most common
cancer in men across SEA and EA respectively. 80% of
new cases are from this region, and are focussed
around Southern China, Taiwan and SEA. Current
research has evaluated the roles of diffusion MRI for
tissue characterisation [7] and 18F-FDG PET for prog-
nostication [8].
In recent years the cancer burden in Asia and its
developing countries has surged, and is forecasted to
continue to rise. Resources for the provision and devel-
opment of diagnostic imaging which plays an essential
role in early detection and management of cancer must
be supported and strengthened across the region.
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